These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 19848437)
1. Cerebrolysin: a review of its use in dementia. Plosker GL; Gauthier S Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437 [TBL] [Abstract][Full Text] [Related]
2. Spotlight on cerebrolysin in dementia. Plosker GL; Gauthier S CNS Drugs; 2010 Mar; 24(3):263-6. PubMed ID: 20155999 [TBL] [Abstract][Full Text] [Related]
3. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Allegri RF; Guekht A Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793 [TBL] [Abstract][Full Text] [Related]
4. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Guekht AB; Moessler H; Novak PH; Gusev EI; J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516 [TBL] [Abstract][Full Text] [Related]
5. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Thome J; Doppler E Drugs Today (Barc); 2012 Apr; 48 Suppl A():63-9. PubMed ID: 22514795 [TBL] [Abstract][Full Text] [Related]
9. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802 [TBL] [Abstract][Full Text] [Related]
12. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic results with Cerebrolysin in the treatment of dementia. Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984 [TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Wei ZH; He QB; Wang H; Su BH; Chen HZ J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304 [TBL] [Abstract][Full Text] [Related]